Tools   Select Another Resource Report Type

http://www.ucl.ac.uk/ion/departments/molecular/themes/neurodegeneration/brainbank

A brain bank which holds an archive of brains donated by individuals with neurodegenerative disease and others who serve as neurologically normal controls. It specializes in parkinsonian movement disorders, including Parkinson's disease and multiple system atrophy, and holds the national collection of brains donated by individuals with progressive supranuclear palsy (PSP). Recently the collection has been developed to include donated brains from prospectively studied people with familial dementias. The QSBB also banks brains donated by people with dystonia and Gilles de la Tourette syndrome. The Brain Bank aims to provide brain tissue for neuropathological studies and for scientific research both in the UK and worldwide. The large collection of tissue is backed up by clinical documentation and all material is fully evaluated by the neuropathologists at QSBB. Brain tissue is stored as formalin-fixed, wax embedded blocks and is frozen, either at -20 degrees C or at -80 degrees C (flash-frozen). Tissue can be provided as slide-mounted sections, or as small blocks for neurochemistry, proteomics and DNA and RNA analysis. Flash-frozen material has excellent histological preservation and is suitable for in situ hybridization and immunohistochemistry. Case-control studies are matched for post-mortem delay and agonal status and are supplied blind.

Proper citation: Queen Square Brain Bank (RRID:SCR_004652) Copy   

•   Source: SciCrunch Registry

http://www.brain-net.net/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 28,2022. A network of several university centers in Germany that classifies neurological and psychiatric disorders neuropathologically and collects and provides brain tissue for research. The aim and task of the Brain-Net are: the collection of clinically and neuropathologically well-characterized brain tissue samples; the standardization of neuropathological diagnoses according to internationally accepted criteria; and providing a basis for future research projects using genetic, epidemiological, biometric and other issues to neurological and psychiatric disorders.

Proper citation: Brain-Net (RRID:SCR_005017) Copy   

•   Source: SciCrunch Registry

Ratings or validation data are available for this resource

http://www.ndriresource.org/

NDRI is a Not-For-Profit (501c3) Corporation dedicated to providing the highest quality human biomaterials for research. NDRI makes it easy for researchers to get the human tissues and organs they need, prepared, preserved and shipped precisely according to their specific scientific protocols, as quickly as possible, and in the largest available quantities. NDRI provides researchers with protocol specific human neurological tissues such as brain stem, spinal cord, and basal ganglia, among others. In addition to control specimens, NDRI recovers tissues from donors with a variety of diseases, including Down syndrome, Parkinsons disease, Alzheimers disease, schizophrenia, and dementia. Through the NDRI 24/7 referral and procurement system, research consented biospecimens can be provided from low post mortem interval donors preserved at 4ºC, frozen or snap frozen, fixed, paraffin embedded, or as unstained slides.

Proper citation: National Disease Research Interchange (RRID:SCR_000550) Copy   

•   Source: SciCrunch Registry

http://www.pd-doc.org/Databases/LinkedDatabases/PSGDatabases/ELLDOPAStudy/tabid/161/Default.aspx

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. This site has a dataset from the ELLDOPA study: a multicenter, placebo-controlled, randomized, dose-ranging, double-blind clinical trial of 361 early, mild Parkinson's disease (PD) subjects, not requiring symptomatic medications with a duration from time of diagnosis less than 2 years. A NINDS funded study. The multicenter, placebo-controlled, randomized, dose-ranging, double-blind clinical trial, called the Earlier versus Later Levodopa Therapy in Parkinson Disease (ELLDOPA) study was run by the Parkinson Study Group and sponsored by the National Institute of Neurological Disorders and Stroke (NINDS). The subjects (n=361) were enrolled between September 1998 and August 2001 at 33 sites in the United States and 5 sites in Canada. Despite the known benefit of levodopa in reducing the symptoms of Parkinsons disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed the effect of levodopa on the rate of progression of Parkinsons disease.The primary analysis assessed the doseresponse relationship between the assigned doses and the worsening of parkinsonism, as indicated by the changes in the total score on the UPDRS between the baseline visit and week 42. Washout of study drug occurred during weeks 40-42.

Proper citation: Earlier versus Later Levodopa Therapy in Parkinson Disease (RRID:SCR_001150) Copy   

•   Source: SciCrunch Registry

http://polygenicpathways.blogspot.com/

A blog concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, autism, Bipolar disorder, multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue.

Proper citation: PolygenicBlog (RRID:SCR_008789) Copy   

•   Source: SciCrunch Registry

http://brainhealthregistry.org/

A website aimed at recruiting and assessing subjects for all types of neuroscience studies with the internet. The hope is to accelerate various types of observational studies and clinical trials, and also reduce costs. They are interested in having people, including healthy subjects of all ages, join the registry. Joining only takes a few minutes. The web-based project is designed to speed up cures for Alzheimer's, Parkinson's and other brain disorders. It uses online questionnaires and online neuropsychological tests (which are very much like online brain games).

Proper citation: Brain Health Registry (RRID:SCR_010230) Copy   

•   Source: SciCrunch Registry

https://scicrunch.org/kravitz2

Dataset of the spike and laser timestamps from Kravitz, Owen and Kretizer's 2012 paper "Optogenetic identification of striatal projection neuron subtypes during in vivo recordings." The code will analyze spike trains around laser pulses to determine if a cell is significantly activated by the laser, and therefore expresses an excitatory opsin, such as channelrhodopsin-2. It returns an excel sheet that simply identifies the activated cells.

Proper citation: Kravitz Dataset 2 (RRID:SCR_000296) Copy   

•   Source: SciCrunch Registry

http://www.orion.fi/en/

A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs.

Proper citation: Orion (RRID:SCR_003911) Copy   

•   Source: SciCrunch Registry

http://www.icdd-sas.com/

A contract research organization (CRO) that are mitochondrial experts, operating mitochondrial function screening platforms by using accepted pharmaceutical innovative technologies. The dynamic analysis of several typical markers of central and mitochondrial metabolism, redox status, or mitochondrial biogenesis are included in the determination of bioenergetic balance in living cells of human origin. These platforms are used to validate the activity of pharmaceuticals, cosmetics and environmental assets xenobiotics on mitochondrial targets associated with the activity or toxicity of these products under the selected models. They specialize in the selection of drugs affecting the progression of neurodegenerative diseases and offer proven models of Huntington's disease, Parkinson's and Alzheimer's, using primary cells of human origin. They have developed and use technology cellulomique and proteomics to identify early response profiles and clinical safety of pharmaceutical products for diseases of the CNS.

Proper citation: Innovative Concepts in Drug Development (RRID:SCR_003940) Copy   

•   Source: SciCrunch Registry

http://www.opko.com/

A multi-national pharmaceutical and diagnostics company that develops, manufactures, and distributes an extensive array of diagnostics and therapeutics for a wide range of indications and conditions. They focus on production of cardiovascular products, vaccines, hormones, antibiotics, gastrointestinal products, and eye care. The company operates in the U.S., Chile, Israel, Mexico, Uruguay, and Spain. (Adapted from Wikipedia)

Proper citation: OPKO (RRID:SCR_004035) Copy   

•   Source: SciCrunch Registry

http://www.fnih.org/

A public charity whose mission is to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. Its vision is Building Partnerships for Discovery and Innovation to Improve Health. The FNIH draws together the world''s foremost researchers and resources, pressing the frontier to advance critical discoveries. They are recognized as the number-one medical research charity in the countryleveraging support, and convening high level partnerships, for the greatest impact on the most urgent medical challenges we face today. Grants are awarded as part of a public-private partnership with the National Heart, Lung, and Blood Institute (NHLBI) on behalf of The Heart Truth in support of women''s heart health education and research. Funding for the Community Action Program is provided by the FNIH through donations from individuals and corporations including The Heart Truth partners Belk Department Stores, Diet Coke, and Swarovski. Successful biomedical research relies upon the knowledge, training and dedication of those who conduct it. Bringing multiple disciplines to bear on health challenges requires innovation and collaboration on the part of scientists. Foundation for NIH partnerships operate in a variety of ways and formats to recruit, train, empower and retain their next generation of researchers. From lectures and multi-week courses, to scholarships and awards through fellowships and residential training programs, their programs respond to the needs of scientists at every level and stage in their careers.

Proper citation: Foundation for the National Institutes of Health (RRID:SCR_004493) Copy   

•   Source: SciCrunch Registry

http://www.stereologyresourcecenter.com/

A company of professionally trained stereologists, bioscientists, computer engineers, educators, and support personnel that provides comprehensive neurostereology products and services to the global bioscience community. These products and services include: stereology and image analysis software, digital imaging technology, turnkey stereologer solutions, comprehensive stereology and image analysis/image processing software, professional contract services, neurostereology workshops, basic stereology courses, and online stereology webinars. The Center also offers tissue processing (sectioning, staining, slide preparation) and stereology data collection services. Researchers may use equipment and facilities to complete projects with full confidentiality and according to Good Laboratory Practices guidelines.

Proper citation: Stereology Resource Center (RRID:SCR_003137) Copy   

•   Source: SciCrunch Registry

http://www.remynd.com/

Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

Proper citation: reMYND (RRID:SCR_003824) Copy   

•   Source: SciCrunch Registry

http://www.patientslikeme.com/

A for-profit health data-sharing platform that can transform the way patients manage their conditions, change the way industry conducts research and improve patient care. PatientsLikeMe aligns patient and industry interests through data-sharing partnerships. They work with trusted nonprofit, research and industry Partners who use this health data to improve products, services and care for patients. They take the information patients share about their experience with the disease and sell it to their partners (i.e., companies that are developing or selling products to patients). These products may include drugs, devices, equipment, insurance, and medical services. Except for the restricted personal information entered when registering for the site, participants should expect that every piece of information submitted (even if it is not currently displayed) may be shared with their partners and any member of PatientsLikeMe, including other patients. They do not rent, sell or share personally identifiable information for marketing purposes or without explicit consent. Because they believe in transparency, they tell members exactly what they do and do not do with their data. Patients have the opportunity to share both personal stories and health data about their conditions to help uncover great ideas and new knowledge. By sharing information on the site, they can put their disease experiences in context and find answers to the questions they have. Every partnership we develop must bring them closer to aligning patient and industry interests. Their end goal is improved patient care and quality of life.

Proper citation: PatientsLikeMe (RRID:SCR_003781) Copy   

•   Source: SciCrunch Registry

http://www.ppmi-info.org/

An observational longitudinal clinical study partnership to identify and validate biomarkers of Parkinson disease (PD) progression and provide easy and open web-based access to the comprehensive set of correlated clinical data and biospecimens, information, and biosamples acquired from PD and age and gender matched healthy control subjects to the research community. The data and specimens have been collected in a standardized manner under strict protocols and includes clinical (demographic, motor and non-motor, cognitive and neurobehavioral), imaging (raw and processed MRI, SPECT and DAT), and blood chemistry and hematology subject assessments and biospecimen inventories (serum, plasma, whole blood, CSF, DNA, RNA and urine). All data are de-identified to protect patient privacy. PPMI will be carried out over five years at 21 clinical sites in the United States and Europe and requires the participation of 400 Parkinson's patients and 200 control participants. The PPMI database provides researchers with access to correlated clinical and imaging data, along with annotated biospecimens, all available within an open access system that encourages data sharing (http://www.ppmi-info.org/access-data-specimens/). The website hosts an Ongoing Analysis section to keep the scientific community apprised of analyses being completed, in hopes of stimulating collaborations between researchers who are using PPMI data and specimens.

Proper citation: Parkinson's Progression Markers Initiative (RRID:SCR_006431) Copy   

•   Source: SciCrunch Registry

http://bioinformatics.ust.hk/MegaSNPHunter.html

Software application that takes case-control genotype data as input and produces a ranked list of multi-SNP interactions. In particular, the whole genome is first partitioned into multiple short subgenomes and a boosting tree classifier is built for each subgenomes based on multi-SNP interactions and then used to measure the importance of SNPs. The method keeps relatively more important SNPs from all subgenomes and let them compete with each other in the same way at the next level. The competition terminates when the number of selected SNPs is less than the size of a subgenome. (entry from Genetic Analysis Software)

Proper citation: MEGASNPHUNTER (RRID:SCR_009287) Copy   

•   Source: SciCrunch Registry

http://www.dna-network.ac.uk/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on October 6, 2011. A project to collect, store and study DNA samples from tens of thousands of healthy volunteers and patients with diseases of major public importance. It aims to identify genes that are risk factors for the conditions. The network consists of 13 collections led by different clinicians throughout the UK. At its heart is an archive infrastructure which manages the DNA and the information associated with it. The European Collection of Cell Cultures in Porton Down handles the blood, peripheral blood lymphocytes and EBV-transformed cell lines, while the Centre for Integrated Genomic Medical Research at Manchester University manages the DNA. These banked samples are available to UK and international researchers, who can examine data and set up collaborative work by registering at the DNA Network's website. The conditions for which samples are currently collected and stored are: Acute leukemia, Asthma and eczema, Late onset Alzheimer's disease, Breast cancer, Colorectal cancer, Coronary artery disease, Glomerulonephritis, Hypertension, Age-related macular degeneration, Multiple sclerosis, Parkinson's disease, Type 2 diabetes, Unipolar depression.

Proper citation: UK DNA Banking Network (RRID:SCR_010619) Copy   

•   Source: SciCrunch Registry

http://westonbraininstitute.ca/

Canadian granting agency to address the existing translational funding gap in neurodegenerative research of the aging population with a goal of accelerating the development of therapeutics and to encourage innovation in the granting process. To achieve this they address gaps and inefficiencies in the funding market by supporting high-risk, high-reward projects independent of commercial potential, while leveraging world-class business and scientific expertise to build a fast and flexible granting process. The Weston Brain Institute is committing up to $10 million in funding across Canada, each year, through various programs and partnerships. The Weston Brain Institute has ongoing collaborative relationships with the Alzheimer's Drug Discovery Foundation - Canada, Brain Canada, the Michael J. Fox Foundation, as well as a group of scientific advisors chaired by Dr. Andres Lozano.

Proper citation: Weston Brain Institute (RRID:SCR_004016) Copy   

•   Source: SciCrunch Registry

http://www.parkinsons.va.gov/New_Front_Page.asp

An organization involved in the clinical research of Parkinson's disease. They are involved in a variety of clinical research including: deep brain stimulation (DBS), drug therapies, gait and falling issues, depression and other psychiatric problems, non-motor fluctuations, basic science and olfactory function during Parkinson's disease.

Proper citation: Parkinson's Disease Research, Education and Clinical Center (RRID:SCR_008099) Copy   

•   Source: SciCrunch Registry

http://www.grc.nia.nih.gov/

A research program of the NIA which focuses on neuroscience, aging biology, and translational gerontology. The central focus of the program's research is understanding age-related changes in physiology and the ability to adapt to environmental stress, and using that understanding to develop insight about the pathophysiology of age-related diseases. The IRP webpage provides access to other NIH resources such as the Biological Biochemical Image Database, the Bioinformatics Portal, and the Baltimore Longitudinal Study of Aging., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Intramural Research Program (RRID:SCR_012734) Copy   

•   Source: SciCrunch Registry